TB-500

Background

Thymosin Beta-4 (TB4) is a 43-amino-acid protein first isolated from the thymus in the early 1980s. It is the most abundant member of the beta-thymosin family and the primary G-actin sequestering protein in most mammalian cells.

TB-500 is the marketing name for a synthetic peptide marketed as a 17-amino-acid fragment of TB4 containing the actin-binding region. Confusingly, "TB-500" and "Thymosin Beta-4" are often used interchangeably in the research peptide market, even though the synthetic short fragment and the recombinant full-length protein are not pharmacologically identical.

Mechanism in depth

The dominant proposed mechanisms:

1. G-actin sequestration — TB4 binds monomeric G-actin in a 1:1 stoichiometry and prevents premature polymerization. This regulates the cytoskeletal dynamics that underlie cell migration, division, and wound contraction.
2. ILK and Akt signaling — TB4 activates integrin-linked kinase, which promotes survival signaling in cardiomyocytes and endothelial cells.
3. Anti-inflammatory effects — reduces pro-inflammatory cytokine production in injured tissue, partially through inhibition of NF-κB.
4. Angiogenesis — increases endothelial cell migration and capillary tube formation in vitro; effects partially overlap with VEGF signaling.

How much of this applies to the short TB-500 fragment vs the full-length protein is an open question — much of the cited mechanism literature uses full-length recombinant TB4.

Human evidence

Sparse for TB-500 specifically; somewhat more for full-length TB4:

• RegeneRx (now ReGenTree) ran phase II trials of full-length TB4 (RGN-259 ophthalmic, RGN-352 cardiac, RGN-137 dermal) with mixed and modest results. Dry-eye and neurotrophic keratopathy showed signal; cardiac program was halted.
• No published RCTs of the synthetic short TB-500 fragment exist for orthopedic or recovery indications.
• Veterinary use, particularly in racehorses for soft-tissue injuries, is widespread and has been the subject of regulatory action by horse racing authorities.

Animal evidence

Robust. Reproducible effects in:

• Skin wound healing models (faster re-epithelialization)
• Corneal injury models
• Myocardial infarction models (reduced scar, preserved function)
• Tendon and ligament repair models
• Spinal cord and peripheral nerve injury models

The mechanism (actin sequestration → cell migration → wound repair) is well-defined and consistent across tissues.

Stack synergy

The canonical stack:

• BPC-157 — the "healing stack." Mechanisms are complementary: BPC-157 drives angiogenesis and growth factor expression; TB-500 drives cellular migration into the new vasculature. There is no published head-to-head or combination trial, but the rationale is mechanistically sound and the pairing is the most common recovery protocol in the research community.
• GHK-Cu — for skin, hair, and connective tissue protocols.
• IGF-1 LR3 or growth hormone secretagogues — anabolic stacking.

No documented pharmacological conflicts.

Open questions

• Is the 17-amino-acid fragment pharmacologically equivalent to full-length TB4? Vendor products labeled "TB-500" may differ in actual peptide identity.
• What is the long-term safety profile with repeated cycles?
• Why did the cardiac repair program stall — toxicity, efficacy, or commercial reasons?
• Does TB-500 promote occult tumor growth at the relevant doses? Animal cancer models give equivocal answers.